Expert Opinion on Investigational Drugs This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Emerging experimental drugs in clinical trials for migraine: observations and key talking points
Expert Opin Investig Drugs. 2023 Sep 8:1-11. doi: 10.1080/13543784.2023.2254691. Online ahead of print.ABSTRACTINTRODUCTION: There have been significant advances in the treatment of migraine. In response to the clinical success of monoclonal antibodies targeting calcitonin gene-related peptide, there is interest in the clinical trial outcomes of alternative emerging drugs that act on novel targets associated with migraine pathophysiology. As approximately 50% of patients do not respond to CGRP therapies, there is significant value in future drug innovation. Emerging drugs in clinical trials for the treatment of migraine ai...
Source: Expert Opinion on Investigational Drugs - September 6, 2023 Category: Drugs & Pharmacology Authors: William David Wells-Gatnik Tiffany Yazmin Wences Chirino Fatma Nur Onan Dilara Onan Paolo Martelletti Source Type: research

Emerging experimental drugs in clinical trials for migraine: observations and key talking points
Expert Opin Investig Drugs. 2023 Sep 6. doi: 10.1080/13543784.2023.2254691. Online ahead of print.ABSTRACTINTRODUCTION: There have been significant advances in the treatment of migraine. In response to the clinical success of monoclonal antibodies targeting calcitonin gene-related peptide, there is interest in the clinical trial outcomes of alternative emerging drugs that act on novel targets associated with migraine pathophysiology. As approximately 50% of patients do not respond to CGRP therapies, there is significant value in future drug innovation. Emerging drugs in clinical trials for the treatment of migraine aim to ...
Source: Expert Opinion on Investigational Drugs - September 6, 2023 Category: Drugs & Pharmacology Authors: William David Wells-Gatnik Tiffany Yazmin Wences Chirino Fatma Nur Onan Dilara Onan Paolo Martelletti Source Type: research

Design strategy and research progress of multifunctional nanoparticles in lung cancer therapy
Expert Opin Investig Drugs. 2023 Sep 5. doi: 10.1080/13543784.2023.2254683. Online ahead of print.ABSTRACTINTRODUCTION: Lung cancer is one of the cancer types with the highest mortality rate, exploring a more effective treatment modality that improves therapeutic efficacy while mitigating side effects is now an urgent requirement. Designing multifunctional nanoparticles can be used to overcome the limitations of drugs and conventional drug delivery systems. Nanotechnology has been widely researched, and through different needs, suitable nanocarriers can be selected to load anti-cancer drugs to improve the therapeutic effec...
Source: Expert Opinion on Investigational Drugs - September 5, 2023 Category: Drugs & Pharmacology Authors: Shen Hui Min Wang Lei Chen Jia Jun Zhang Shao Yan Yang Xu Guang Zhang Tong Zheng Pei Yong Lu Zheng Hui Huang Xing Source Type: research

A phase-I randomized euglycemic clamp study to demonstrate the pharmacokinetic and pharmacodynamic equivalence of an insulin degludec biosimilar (B01411) with the reference product in healthy Chinese volunteers
CONCLUSION: B01411 exhibited a pharmacokinetic and pharmacodynamic similarity to the reference product. Both IDeg products were well tolerated.CLINICAL TRIAL REGISTRATION: http://www.chinadrugtrials.org.cn/index.html#. Identifier is CTR20192122.PMID:37665683 | DOI:10.1080/13543784.2023.2254690 (Source: Expert Opinion on Investigational Drugs)
Source: Expert Opinion on Investigational Drugs - September 4, 2023 Category: Drugs & Pharmacology Authors: Hui Liu Ting Li Hongling Yu Xinlei Chen Jiaqi Li Huiwen Tan Dejia Jia Yerong Yu Source Type: research

Investigational monoclonal antibodies in early development for psoriatic arthritis: beyond the biosimilars
This article reviews available results from phase I to phase III trials of several investigational monoclonal antibodies that the FDA has not yet approved for PsA. The proposed mechanisms of the new therapeutic agents and their relevance to the pathogenesis of PsA will be discussed. The investigational agents' efficacy and safety will be summarized, and their potential clinical applications for managing PsA will be contemplated.EXPERT OPINION: Due to recent advances in understanding psoriatic arthritis, therapeutic agents are increasingly focused on inhibiting interleukin-17 and interleukin-23 pathways. Various strategies ...
Source: Expert Opinion on Investigational Drugs - September 1, 2023 Category: Drugs & Pharmacology Authors: Anna Edwards Vinod Chandran Proton Rahman Source Type: research